Over the last 25 years, asthma has emerged as an increasingly important public health problem ([@b2-ehp0116-000409]; [@b29-ehp0116-000409]). The pathogenesis and etiology of asthma is complex and not fully understood. Although a rapid rise in childhood asthma prevalence suggests a role for environmental factors in the etiology of this evolving epidemic, genetic susceptibility to environmental stressors is also likely to influence the occurrence of asthma ([@b5-ehp0116-000409]; [@b7-ehp0116-000409]; [@b19-ehp0116-000409]).

Evidence suggests that members of the glutathione *S*-transferase (GST) superfamily contribute to asthma pathogenesis. We have previously reported that *GSTM1* is associated with asthma risk in children exposed to tobacco smoke ([@b14-ehp0116-000409]). The GST superfamily includes a number of additional candidate susceptibility genes for asthma because several members, including *GSTP1,* are expressed in the respiratory tract and function in processes implicated in asthma pathogenesis, including oxidant defenses, xenobiotic metabolism, and detoxification of hydroperoxides ([@b33-ehp0116-000409]). DNA sequence variants in the *GSTP1* locus may contribute to susceptibility to oxidative stress and airway inflammation, which are key processes in asthma pathogenesis. A functional sequence variant in *GSTP1* at codon 105 (Ile105Val) has been associated with asthma and susceptibility to the adverse effects of tobacco smoke and ambient air pollution in several studies ([@b3-ehp0116-000409]; [@b9-ehp0116-000409]; [@b10-ehp0116-000409]; [@b13-ehp0116-000409], [@b15-ehp0116-000409]; [@b18-ehp0116-000409]; [@b21-ehp0116-000409], [@b20-ehp0116-000409]; [@b24-ehp0116-000409]; [@b26-ehp0116-000409]; [@b30-ehp0116-000409]; [@b34-ehp0116-000409]). Although evidence indicates a role of the GSTP1 Ile105Val variant in asthma, the effect of other common variants in *GSTP1* coding and promoter region and the joint effects with tobacco-smoke exposure have yet to be fully determined.

The human genome is characterized by regions of strong linkage disequilibrium (LD) that have been labeled as haplotype blocks by [@b11-ehp0116-000409]. The common genetic variation across the region can be predicted using only a subset of all single nucleotide polymorphisms \[haplotype tagging SNPs (htSNPs)\] ([@b32-ehp0116-000409]). These can be used to impute haplotypes and provide an indirect assessment of potential common causal variants that may not have been genotyped. To further investigate the effect of common *GSTP1* variants to asthma occurrence and susceptibility to tobacco smoke, we examined associations between common *GSTP1* haplotypes, tobacco-smoke exposure, childhood asthma, and related symptoms among participants in the Children's Health Study.

Methods
=======

Study population
----------------

The Children's Health Study (CHS) recruited children from public school classrooms from grades 4, 7, and 10 in 12 Southern California communities. At study entry, in the spring of 1993, a parent or guardian of each participating child completed a self-administered questionnaire on demographics, medical and family health history, smoking exposures, and household characteristics. In the fall of 1995, a second group of fourth-grade students was recruited and completed the same baseline questionnaire as the group enrolled in 1993. A parent or guardian of each participating child provided written informed consent. Details on the design, site selection, subject recruitment, and assessment of health effects have previously been reported ([@b14-ehp0116-000409]; [@b28-ehp0116-000409]). This analysis included 3,082 non-Hispanic and Hispanic white children who participated in the genetic studies. Children and a subset of their parents (579 child--parent trios) provided buccal cell specimens as a source of germline DNA for genotyping.

Outcome assessment: asthma/wheezing
-----------------------------------

We used questionnaire responses provided by parents or guardians to categorize children's asthma status, age at asthma diagnosis, and wheezing history as previously described ([@b14-ehp0116-000409]; [@b22-ehp0116-000409]). Children were classified as having a lifetime diagnosis of asthma if the adult completing the questionnaire reported that a doctor had ever diagnosed the child as having asthma. Asthma onset by 3 years of age was classified as early-onset asthma. Late-onset asthma was defined as age of onset for asthma after 3 years of age. Current wheezing was defined as a positive response to both of the following questions: "Has your child ever wheezed? If yes, has this happened in the past 12 months?" Any medication for wheezing was assessed for the 12 months before the interview.

Exposure assessment
-------------------

Exposure assessment methods have been previously reported ([@b14-ehp0116-000409]; [@b28-ehp0116-000409]). In brief, exposure to maternal smoking during the *in utero* period, secondhand-smoke exposure, and the number of smokers in the household were collected by questionnaire at study entry. Ambient air pollutants were monitored at central site monitors located in each of the study communities, and average annual exposure levels were computed. Monitored pollutants included ozone, nitrogen dioxide, and particulate matter with an aerodynamic diameter of up to 2.5 μm or 10μm (PM~2.5~ and PM~10~).

Genotyping
----------

Buccal scrapes were collected using standard protocols, and genomic DNA was isolated using a PURGENE DNA isolation Kit (Gentra Systems, Minneapolis, MN, USA). The polymorphisms were identified using allele-specific MGB probes on an ABI PRISM 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA). The sequences of primers and probes used are listed in the Supplemental Material, [Table 1](#t1-ehp0116-000409){ref-type="table"} (online at <http://www.ehponline.org/members/2007/10655/suppl.pdf>).

Characterizing LD and selecting htSNPs
--------------------------------------

To investigate the LD patterns for *GSTP1*, we examined resequencing data for *GSTP1* in a panel of 90 subjects provided by the National Institute of Environmental Health Sciences (NIEHS) Environmental Genome Project (<http://egp.gs.washington.edu/>) ([@b25-ehp0116-000409]) to characterize the haplotype block structure by using Haploview version 3.3 (download from <http://www.broad.mit.edu/mpg/haploview/download.php>) ([@b4-ehp0116-000409]). One sample was not included because only 40% of the SNPs had genotyping results. Twenty-six of the 36 SNPs found in the sequencing were excluded because of a lower minor allele frequency (MAF ≤ 0.20) or a high missing rate (≥25%) among samples.

As shown in [Figure 1](#f1-ehp0116-000409){ref-type="fig"}, two haplotype blocks with substantial interblock LD were defined based on the method using the confidence intervals (CIs) of D′ proposed by [@b11-ehp0116-000409] (with the upper CI as 0.97 and the lower CI as 0.70). The squared correlation (*R*~h~^2^) between the true haplotypes (h) and their estimates were calculated, and the calculation of *R*~h~^2^ is described in detail by [@b32-ehp0116-000409]. The htSNPs were then chosen using TagSNPs (download from <http://www-rcf.usc.edu/~stram/tagSNPs.html>) ([@b31-ehp0116-000409]). This program implements an expectation maximization (EM) algorithm approach to find the minimum set of SNPs (within a block) that would have *R*~h~^2^ ≥0.85 for all haplotypes with an estimated frequency of ≥ 5%. We selected two htSNPs for each of the two blocks (rs6591255 and rs4147581 for the first block with *R*~h~^2^ = 0.87; rs1695 and rs749174 for the second block with *R*~h~^2^ = 0.91). All four htSNPs accounted for 83% of the haplotypic variation in the *GSTP1* locus without considering the block structure.

Statistical analyses
--------------------

### SNP-based analysis

We first examined the association of each of the four *GSTP1* htSNPs with asthma and wheezing outcomes using multiple logistic regressions. Models were adjusted for *a priori* selected covariates including communities of residence, sex, age, gestational age, and smoke exposure (both *in utero* and secondhand). We used the dominant genetic model to assess the association of each htSNP with asthma and wheezing outcomes. We performed a likelihood ratio test (LRT) to test the global association of four variants in *GSTP1* with asthma and wheezing outcomes. To assess confounding by admixture, we examined genotype associations in child--parent trios using a logistic-regression model that included indicators of parent mating type ([@b12-ehp0116-000409]). In addition, we stratified our study population by non-Hispanic and Hispanic whites (two major ethnic groups) to assess whether associations differed by ethnicity. We formally tested for ethic differences in associations, and if effect estimates and test of significance supported no ethnic differences, the analyses were conducted in the combined group with adjustment for ethnicity.

### Haplotype-based analysis

Because phase cannot be uniquely defined for subjects that have heterozygous genotypes, haplotype frequencies for each ethnic group (non-Hispanic and Hispanics whites) were separately estimated from the genotype data using the EM algorithm. Following the method of [@b36-ehp0116-000409] and [@b35-ehp0116-000409], we coded the haplotype as the (estimated) number of copies of each haplotype a person carries. For example, if one individual carries one copy of haplotype A and one copy of haplotype B, the coding for haplotype A and B would be one, and the coding for the rest of the haplotypes could be zero. The sum of all number of copies of each haplotype for a person should be two. Except for the most common haplotype, which was the referent haplotype in the analysis, these (estimated) numbers of copies of each haplotype a person carries were used in a logistic model with the same adjustment variables listed above. Thus, the odds ratio (OR) for the outcome represents the increase in risk for a single copy of a particular haplotype relative to the referent haplotype ([@b35-ehp0116-000409]). The most common haplotype was used as the reference in the haplotype-based analysis. Moreover, likelihood ratio tests with 5 degrees of freedom were performed for the omnibus test of haplotype association. All statistical analyses were carried out by SAS version 9.1 (SAS Institute Inc., Cary, NC, USA), and all tests were two-sided with 0.05 as the significant level.

Results
=======

The characteristics of participants in this study are described in [Table 1](#t1-ehp0116-000409){ref-type="table"}. Most children were non-Hispanic white and \< 10 years of age. *In utero* exposure to maternal smoking occurred among 19.8% of non-Hispanic whites and 10.7% of Hispanic whites. Personal smoking was rare in both ethnic groups (about 1%). Similar percentages of non-Hispanic whites and Hispanic whites (15.3% and 13.8%, respectively) reported any lifetime diagnosis of asthma. The prevalence of wheezing in the preceding 12 months was 19.9% and 16.8% for non-Hispanic and Hispanic whites, respectively. About 11% of participants took medication for wheezing.

The genotype frequencies of the four *GSTP1* htSNPs are presented in [Table 2](#t2-ehp0116-000409){ref-type="table"}, and the pairwise measures (D′ and *r*^2^) of linkage disequilibrium (LD) are shown in [Table 3](#t3-ehp0116-000409){ref-type="table"}. The genotype distributions of the four SNPs were consistent with Hardy--Weinberg equilibrium. The allele frequencies of these SNPs differed in non-Hispanic and Hispanic whites, and the four htSNPs appeared to show stronger LD across the locus in non-Hispanic whites than in Hispanic whites.

In the SNP-based analysis, the four *GSTP1* SNPs jointly explained a statistically significant portion of the occurrence of lifetime asthma and wheezing occurrences ([Table 4](#t4-ehp0116-000409){ref-type="table"}). The overall pattern of associations was similar in non-Hispanic and Hispanic whites, although the association was statistically significant only in non-Hispanic whites, a finding likely attributable to the larger sample size of non-Hispanic whites. The variant allele of SNP1 was associated with an increased risk for all asthma and wheezing outcomes with no important ethnic differences in the magnitudes of the associations. Carrying one variant allele of SNP2 was protective for asthma and wheezing, although the association reached statistical significance for lifetime asthma and early-onset asthma, again with little evidence for ethnic differences in effects. The variant allele of SNP3 (Ile105Val) was associated with an increased risk of early-onset asthma. SNP4 showed a similar pattern with asthma and wheezing as SNP1.

Based on *a priori* knowledge that SNP1 and SNP3 are not in strong LD ([Table 4](#t4-ehp0116-000409){ref-type="table"}) and may produce functional differences in the expression and/or enzymatic function, respectively, we fitted reduced models that include only these two SNPs ([Table 5](#t5-ehp0116-000409){ref-type="table"}). The joint model of the two functional SNPs provided the best fit to these data and showed that carrying a variant allele of SNP1 increased the risk of asthma and wheezing, but having a variant allele of SNP3 did not have a significant association with asthma and wheezing. Because the CHS cohort actually represented two discrete enrollment periods (a fourth-, seventh-, and tenth-grade group recruited in 1993 and an additional fourth-grade contingent in 1996), we examined whether associations were also observable in the two independent groups. The results were consistent in these two groups, and the stronger association of SNP1 compared with SNP3 was observed in the two CHS cohorts \[Supplemental Material, [Table 2](#t2-ehp0116-000409){ref-type="table"} (online at <http://www.ehponline.org/members/2007/10655/suppl.pdf>)\].

Haplotype frequencies defined using the four *GSTP1* htSNPs are shown in [Table 6](#t6-ehp0116-000409){ref-type="table"}. The number and frequency of haplotypes varied among non-Hispanic and Hispanic whites. For example, the haplotype carrying the variant allele for SNP3 and common alleles for the other three SNPs (henceforth labeled h0010) was rare in non-Hispanic whites (frequency = 0.008) and relatively common in Hispanic whites (frequency = 0.209). With one exception, we collapsed the rare haplotypes with frequency \< 0.05 into a single composite category for data analysis as indicated in [Table 6](#t6-ehp0116-000409){ref-type="table"} \[leaving only the haplotype that isolates the Ile105Val variant as a separate category (h0010)\].

Variation in the upstream region of the locus was associated with asthma and wheezing. Although the omnibus test of haplotype association (by the likelihood ratio test with 5 degrees of freedom) was only statistically significant in the combined group, haplotypes containing the variant allele of SNP1 (i.e., h1000 and h1011) were associated with an increased risk of asthma ([Table 7](#t7-ehp0116-000409){ref-type="table"}). Compared with having two copies of the most common haplotype (h0100), people with a copy of h1000 were at a 1.3-fold higher risk of lifetime diagnosis of asthma (95% CI, 1.0--1.7). Children with the haplotype h1011 showed an increased risk for the lifetime diagnosis of asthma compared with children carrying the reference haplotype. In contrast, the h0010 haplotype (105Val with no other variants) was associated with a reduced risk for current wheezing. There were no significant ethnic differences in these associations.

We have previously reported that variants in GSTs affect the risk of asthma associated with maternal smoking ([@b14-ehp0116-000409]). To further investigate the effect of *GSTP1* variants on the relationship between *in utero* exposure to maternal smoking and asthma/wheezing outcomes, we examined the joint effects of the common haplotype and *in utero* exposure to maternal smoking in both ethnic groups combined because there was little evidence for ethnic heterogeneity in associations. Among the common haplotypes shown in [Table 6](#t6-ehp0116-000409){ref-type="table"}, the effects of maternal smoking on wheezing were significantly larger in those with h0010 compared with the other haplotypes ([Table 8](#t8-ehp0116-000409){ref-type="table"}). The same pattern of effects was observed in the h1011 haplotype ([Table 9](#t9-ehp0116-000409){ref-type="table"}). Because the haplotype associations involved the *GSTP1* Ile105Val SNP, we then investigated the relationship between the Ile105Val variant, *in utero* exposure to maternal smoking and asthma/wheezing outcomes ([Table 10](#t10-ehp0116-000409){ref-type="table"}). Compared with those with no exposure and homozygous Ile 105 genotype, children exposed to *in utero* maternal smoking and carrying at least one variant *GSTP1* Ile105Val allele had about twice the risk of current wheezing and requiring medication for wheeze (OR = 1.9 for both; and 95% CI, 1.3--2.6 and 1.2--2.8, respectively; interaction *p*-value = 0.04 for both). Consistent with an important role of the Val105 variant in the association between *in utero* exposure to maternal smoking and asthma/wheezing, h1011 modified the effect of *in utero* exposure to maternal smoking ([Table 9](#t9-ehp0116-000409){ref-type="table"}); however, SNP1 and SNP4 did not modify the association in the SNP-based analyses.

To assess the potential for confounding by admixture, we investigated the genetic associations in a cohort subsample of 579 child--parent trios (for both diseased and nondiseased children). The trio analysis showed that the risk estimates were generally consistent with the results for the entire cohort. The point estimates for SNP1 and SNP4 were higher \[Supplemental Material, [Table 3](#t3-ehp0116-000409){ref-type="table"} (online at <http://www.ehponline.org/members/2007/10655/suppl.pdf>)\], but the confidence-intervals width was about twice as wide in the trio analysis as in the main study, reflecting the smaller sample size of complete trios.

The effect of *GSTP1* on asthma and wheezing did not differ with respect to sex, secondhand-smoke exposure, number of smokers in the household, personal smoking, and ambient air pollutants including ozone, nitrogen dioxide, and PM~2.5~ and PM~10~ (data not shown).

Discussion
==========

We found that DNA sequence variants in both the promoter and coding regions of the *GSTP1* locus may contribute to the occurrence of childhood asthma and wheezing. The overall evidence is consistent with a complex age-dependent role in the pathogenesis of asthma and wheezing for the *GSTP1* Ile105Val SNP, which affects enzyme function. Furthermore, the effect of *in utero* exposure to maternal smoking on current wheezing and medication for wheeze depends primarily on the *GSTP1* 105Val variant allele both in the haplotype (h0010) and SNP analyses. Our finding that a potentially functional SNP located in the promoter region of *GSTP1* is associated with asthma is novel and suggests that transcriptional regulation may be important in asthma development.

*GSTP1* is located on chromosome 11q13, a previously suggested candidate region for asthma, bronchial hyperresponsiveness, and asthma-associated quantitative traits in some linkage studies ([@b8-ehp0116-000409]). The mechanism for the effects of *GSTP1* on respiratory illnesses may involve pathways that affect responses to oxidative stress ([@b9-ehp0116-000409]; [@b17-ehp0116-000409]). GSTs contribute to protection against oxidative stress by using glutathione to detoxify a variety of electrophilic compounds including oxidized lipid, DNA, and catechol products generated by reactive oxygen species--induced damage to intracellular molecules ([@b16-ehp0116-000409], [@b17-ehp0116-000409]). Because *GSTP1* is strongly expressed in the respiratory epithelium and is the dominant GST in the lung, variation in *GSTP1* function may have larger effects on respiratory health outcomes than do other members of the GST superfamily. The role of *GSTP1* protecting against reactive oxygen species and their secondary products may be mediated by the 105 variant ([@b27-ehp0116-000409]).

To our knowledge, the association between SNP1 (rs6591255) with asthma and wheezing has not been previously reported. Based on the SNP- and haplotype-based analyses in the present study, such association of SNP1 is not attributable to the LD with the *GSTP1* Ile105Val allele. This SNP is located in a putative transcription factor 1 (TCF-1) binding site upstream of the transcription start site and may potentially be a functional SNP. However, the role of TCF-1 in asthma pathogenesis has yet to be determined. The promoter region is complex and could harbor other functional variants in LD with SNP1. [@b6-ehp0116-000409] completely sequenced the promoter region of the *GSTP1* gene in 40 Euro-Caucasian individuals and reported that one common haplotype comprising the common allele of the SNP1 in the present study interacts with chemopreventive exposure in luciferase reporter constructs. This novel finding is consistent with our finding that SNP1 is an upstream SNP important in reducing the risk of asthma and wheezing symptoms. The role of the promoter region of *GSTP1* needs further study to verify whether the association reported here is attributable to LD with another functional SNP or its own functionality as a TCF-1 binding site.

Our study has some potential limitations that may influence the interpretation of our results. We recognize that asthma is a complex disease, and studying only the *GSTP1* gene does not provide a complete picture of genetic susceptibility. Interaction between *GSTP1* and *GSTM1* has been reported for xenobiotic enhancement of allergic responses ([@b15-ehp0116-000409]) and on childhood asthma risk ([@b20-ehp0116-000409]). In the present study, there is insufficient power to assess higher-order interactions between *GSTP1* SNPs and haplotypes with other genes and smoking.

Selection bias is a common concern in cross-sectional studies. The group of children with genotyping data included in this analysis did not differ substantially from those without genotyping data on a broad range of demographic, medical history, and household exposure factors \[Supplemental Material, [Table 4](#t4-ehp0116-000409){ref-type="table"} (online at <http://www.ehponline.org/members/2007/10655/suppl.pdf>)\]. Therefore, selection bias is an unlikely explanation for our findings. Another possible limitation might be recall bias with regard to early life events. To evaluate this possibility, we resurveyed 691 study participants about the mother's smoking history during pregnancy and about asthma status in a counter-matched case--control study nested in the CHS ([@b23-ehp0116-000409]) as we tried to investigate the dose effect of smoking. The kappa coefficients for the agreement between the two repeated measurements were 0.80 and 0.75 for asthma and smoking, respectively. The agreement is acceptable, especially as the agreement of smoking was not statistically significantly different by asthma status. We assessed recall of asthma status in the same nested case--control study and found that the concordance of parental reports of asthma and medical records' documentation of asthma was good. Based on the 2001 National Health Interview Survey, it was estimated that 113.4 per 1,000 Americans had been diagnosed with asthma by a physician in their lifetime, and, among children 5--17 years of age, the lifetime prevalence was 144.2 per 1,000 which was close to the prevalence of asthma in the present study ([@b1-ehp0116-000409]). Moreover, we observed the same results when we excluded early transient wheezing cases \[Supplemental Material, [Table 5](#t5-ehp0116-000409){ref-type="table"} (online at <http://www.ehponline.org/members/2007/10655/suppl.pdf>)\]. Population stratification can be a concern in genetic association studies. In our investigation, although the estimates were more uncertain because of a smaller sample size in the trio analyses, the case--control and complete trio analyses indicate that confounding by population substructure is unlikely to explain our findings.

Some of our results were based on a haplotype approach. The selection of htSNPs was based on 90 individual genotypes provided by the NIEHS Environmental Genome Project. Although haplotype analysis is very dependent on the definition of blocks, it was not an issue for the present study because the four SNPs selected for this study represented \> 80% of the general population's variation. The EPG data did not carry ethnicity identifiers, so we could not stratify the data when selecting htSNPs. However, we assessed how well the four selected htSNPs represented the haplotype diversities in two other ethnically identified subgroups, each containing 70 individuals. The *R*~h~^2^ was 0.76 and 0.71 respectively for non-Hispanic and Hispanic whites, implying that the four selected htSNPs had good coverage for the two ethnic groups in the present study. Nevertheless, the ability to detect a true disease variant using a haplotype approach can be attenuated if the variant is distributed across several haplotypes in the population and the Ile105Val allele is split into two major haplotypes in Hispanic whites. In our analyses, we adopted the commonly used approach of clustering rare haplotypes into a composite category. However, this composite category likely included one or more haplotypes carrying the disease variant, thereby reducing the analytical power to contrast this variant against other haplotypes.

In summary, the *GSTP1* locus is associated with asthma and wheezing outcomes in children. Both the well-studied Ile105Val variant and an upstream SNP are associated with the risk of asthma; however, the effects appear to occur in opposite directions. This pattern may explain some of the inconsistencies in previous studies of the 105 variant and asthma. The 105Val allele variant appears to modulate the effects of *in utero* exposure to maternal smoking on asthma and wheezing. Additional studies of sufficient size are needed to independently replicate and expand our findings to investigate sequence variation in the promoter region of the *GSTP1* gene and the interaction of *GSTP1* haplotypes with other genes and environmental/endogenous sources of reactive oxygen species.

Supplemental Material is available online at <http://www.ehponline.org/members/2007/10655/suppl.pdf>
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###### 

Selected characteristics of non-Hispanic and Hispanic white CHS participants.[a](#tfn2-ehp0116-000409){ref-type="table-fn"}

  Demographic characteristics/respiratory outcomes   Non-Hispanic white (*n* = 2,122)   Hispanic white (*n* = 960)
  -------------------------------------------------- ---------------------------------- ----------------------------
  Demographic characteristics                                                           
   Percent female                                    51.7                               56.8
   Age at study entry \[years (%)\]                                                     
    8-- \< 10                                        50.5                               55.8
    10-- \< 12                                       21.4                               22.2
    12-- \< 14                                       15.5                               11.7
    14--18                                           12.5                               10.3
   Gestational age (%)                                                                  
    Full term                                        87.9                               91.2
    \< 4 weeks early                                 7.3                                6.0
    ≥4 weeks early                                   4.7                                2.8
   With insurance (%)                                88.3                               73.9
   Tobacco-smoke exposure (%)                                                           
    *In utero*                                       19.8                               10.7
    Ever SHS                                         36.2                               26.9
    Current SHS                                      19.2                               12.9
    Personal smoking                                 1.1                                0.8
  Respiratory outcomes (%)                                                              
   Lifetime diagnosis of asthma                      15.3                               13.8
   Early-onset asthma                                7.1                                6.9
   Late-onset asthma                                 8.2                                6.9
   Current wheezing                                  19.9                               16.8
   Medication for wheeze                             11.4                               10.2

SHS, secondhand smoke.

Participants with genotyping data.

###### 

Genotype frequencies of four *GSTP1* htSNPs in non-Hispanic and Hispanic white participants in the CHS.[a](#tfn3-ehp0116-000409){ref-type="table-fn"}

                                      Non-Hispanic white   Hispanic white         
  ---------------------------- ------ -------------------- ---------------- ----- ------
  SNP1                         TT     741                  34.9             468   48.8
  (rs6591255)                  TA     1,024                48.3             399   41.6
                               AA     357                  16.8             93    9.7
  Minor allele (A) frequency   0.41   0.31                                        
  SNP2                         CC     527                  24.8             367   38.2
  (rs4147581)                  CG     1,083                51.0             456   47.5
                               GG     512                  24.1             137   14.3
  Minor allele (G) frequency   0.50   0.38                                        
  SNP3                         AA     945                  44.5             279   29.1
  (rs1695)                     AG     944                  44.5             504   52.5
                               GG     233                  11.0             177   18.4
  Minor allele (G) frequency   0.33   0.45                                        
  SNP4                         CC     948                  44.7             539   56.2
  (rs749174)                   CT     948                  44.7             362   37.7
                               TT     226                  10.7             59    6.2
  Minor allele (T) frequency   0.33   0.25                                        

The genotype distributions of the four SNPs are all in the Hardy--Weinberg equilibrium in both ethnic groups.

###### 

Pairwise measures of linkage disequilibrium (*r*^2^[a](#tfn4-ehp0116-000409){ref-type="table-fn"} and D′[b](#tfn5-ehp0116-000409){ref-type="table-fn"}) for the *GSTP1* htSNPs in non-Hispanic and Hispanic white CHS participants.

  D′ \\ *r*^2^         SNP1 (rs6591255)                                      SNP2 (rs4147581)                                      SNP3 (rs1695)                                         SNP4 (rs749174)
  -------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  Non-Hispanic white                                                                                                                                                                     
   SNP1                                                                      0.668[a](#tfn4-ehp0116-000409){ref-type="table-fn"}   0.550[a](#tfn4-ehp0116-000409){ref-type="table-fn"}   0.633[a](#tfn4-ehp0116-000409){ref-type="table-fn"}
   SNP2                0.988[b](#tfn5-ehp0116-000409){ref-type="table-fn"}                                                         0.406[a](#tfn4-ehp0116-000409){ref-type="table-fn"}   0.448[a](#tfn4-ehp0116-000409){ref-type="table-fn"}
   SNP3                0.875[b](#tfn5-ehp0116-000409){ref-type="table-fn"}   0.910[b](#tfn5-ehp0116-000409){ref-type="table-fn"}                                                         0.820[a](#tfn4-ehp0116-000409){ref-type="table-fn"}
   SNP4                0.944[b](#tfn5-ehp0116-000409){ref-type="table-fn"}   0.961[b](#tfn5-ehp0116-000409){ref-type="table-fn"}   0.910[b](#tfn5-ehp0116-000409){ref-type="table-fn"}   
  Hispanic white                                                                                                                                                                         
   SNP1                                                                      0.269[a](#tfn4-ehp0116-000409){ref-type="table-fn"}   0.155[a](#tfn4-ehp0116-000409){ref-type="table-fn"}   0.625[a](#tfn4-ehp0116-000409){ref-type="table-fn"}
   SNP2                1.000[b](#tfn5-ehp0116-000409){ref-type="table-fn"}                                                         0.433[a](#tfn4-ehp0116-000409){ref-type="table-fn"}   0.162[a](#tfn4-ehp0116-000409){ref-type="table-fn"}
   SNP3                0.534[b](#tfn5-ehp0116-000409){ref-type="table-fn"}   0.935[b](#tfn5-ehp0116-000409){ref-type="table-fn"}                                                         0.307[a](#tfn4-ehp0116-000409){ref-type="table-fn"}
   SNP4                0.906[b](#tfn5-ehp0116-000409){ref-type="table-fn"}   0.889[b](#tfn5-ehp0116-000409){ref-type="table-fn"}   0.862[b](#tfn5-ehp0116-000409){ref-type="table-fn"}   

*r*^2^: upper triangle area.

D′: lower triangle area.

###### 

The association \[OR (95% (CI)\] of four *GSTP1* htSNPs[a](#tfn6-ehp0116-000409){ref-type="table-fn"} with asthma and wheezing in CHS participants by single SNP models.

  Ethnicity and outcome                                                         SNP1                                                             SNP2             SNP3                                                             SNP4                                                             LRT[b](#tfn7-ehp0116-000409){ref-type="table-fn"}*p*-Value
  ----------------------------------------------------------------------------- ---------------------------------------------------------------- ---------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------
  Non-Hispanic + Hispanic white[c](#tfn8-ehp0116-000409){ref-type="table-fn"}                                                                                                                                                                                                                       
   Lifetime diagnosis of asthma                                                 1.4 (1.1--1.7)                                                   0.8 (0.6--0.9)   1.2 (1.0--1.5)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   1.3 (1.0--1.5)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.022
   Early-onset asthma                                                           1.4 (1.0--1.8)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.7 (0.5--0.9)   1.3 (0.9--1.8)                                                   1.4 (1.0--1.8)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.142
   Late-onset asthma                                                            1.4 (1.0--1.9)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.8 (0.6--1.0)   1.2 (0.8--1.5)                                                   1.2 (0.9--1.6)                                                   0.109
   Current wheezing                                                             1.3 (1.0--1.6)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   1.0 (0.7--1.1)   1.1 (0.8--1.2)                                                   1.2 (1.0--1.4)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.027
   Medication for wheeze                                                        1.6 (1.2--2.0)                                                   0.9 (0.7--1.2)   1.2 (0.9--1.5)                                                   1.4 (1.1--1.7)                                                   0.004
  Non-Hispanic white[d](#tfn9-ehp0116-000409){ref-type="table-fn"}                                                                                                                                                                                                                                  
   Lifetime diagnosis of asthma                                                 1.5 (1.1--1.9)                                                   0.8 (0.6--1.0)   1.2 (0.9--1.5)                                                   1.2 (0.9--1.5)                                                   0.032
   Early-onset asthma                                                           1.5 (1.0--2.2)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.8 (0.5--1.1)   1.4 (1.0--2.0)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   1.4 (0.9--1.9)                                                   0.209
   Late-onset asthma                                                            1.5 (1.0--2.0)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.8 (0.5--1.0)   1.1 (0.7--1.4)                                                   1.1 (0.8--1.5)                                                   0.090
   Current wheezing                                                             1.4 (1.1--1.7)                                                   0.9 (0.7--1.2)   1.1 (0.8--1.3)                                                   1.2 (0.9--1.4)                                                   0.031
   Medication for wheeze                                                        1.6 (1.2--2.2)                                                   0.9 (0.6--1.2)   1.2 (0.9--1.6)                                                   1.3 (0.9--1.7)                                                   0.024
  Hispanic white[d](#tfn9-ehp0116-000409){ref-type="table-fn"}                                                                                                                                                                                                                                      
   Lifetime diagnosis of asthma                                                 1.3 (0.8--1.9)                                                   0.7 (0.4--1.0)   1.3 (0.8--2.0)                                                   1.5 (1.0--2.1)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.143
   Early-onset asthma                                                           1.1 (0.6--1.8)                                                   0.6 (0.3--1.0)   1.1 (0.6--1.9)                                                   1.3 (0.7--2.2)                                                   0.236
   Late-onset asthma                                                            1.4 (0.8--2.4)                                                   0.8 (0.4--1.3)   1.5 (0.8--2.8)                                                   1.6 (0.9--2.6)                                                   0.469
   Current wheezing                                                             1.2 (0.8--1.7)                                                   1.0 (0.6--1.3)   1.0 (0.7--1.5)                                                   1.5 (1.0--2.1)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.108
   Medication for wheeze                                                        1.5 (0.9--2.4)                                                   1.0 (0.6--1.5)   1.1 (0.7--1.8)                                                   1.7 (1.0--2.6)[\*](#tfn10-ehp0116-000409){ref-type="table-fn"}   0.186

SNP1 (rs6591255): T→A; SNP2 (rs4147581): C→G; SNP3 (rs1695): A→G; and SNP4 (rs749174): C→T.

LRT: comparing the model with the four *GSTP1* htSNPs with the model without the four *GSTP1* htSNPs.

Models are adjusted for communities of residence, sex, age, gestational age, smoke exposure, and Hispanic ethnicity.

Models are adjusted for communities of residence, sex, age, gestational age, and smoke exposure.

*p* \< 0.05 although the confidence upper/lower limit is 1.0.

###### 

Multiple logistic-regression models \[OR (95% CI)\] considering two potential functional *GSTP1* SNPs.[a](#tfn11-ehp0116-000409){ref-type="table-fn"}

  Ethnicity and outcome                                                          SNP1                                                             SNP3             LRT[b](#tfn12-ehp0116-000409){ref-type="table-fn"}*p*-Value
  ------------------------------------------------------------------------------ ---------------------------------------------------------------- ---------------- -------------------------------------------------------------
  Non-Hispanic + Hispanic white[c](#tfn13-ehp0116-000409){ref-type="table-fn"}                                                                                     
   Lifetime diagnosis of asthma                                                  1.4 (1.0--1.8)[\*](#tfn15-ehp0116-000409){ref-type="table-fn"}   1.0 (0.7--1.3)   0.008
   Early-onset asthma                                                            1.2 (0.8--1.7)                                                   1.2 (0.8--1.7)   0.090
   Late-onset asthma                                                             1.5 (1.0--2.1)[\*](#tfn15-ehp0116-000409){ref-type="table-fn"}   0.9 (0.6--1.2)   0.033
   Current wheezing                                                              1.5 (1.1--1.8)                                                   0.9 (0.6--1.0)   0.009
   Medication for wheeze                                                         1.7 (1.2--2.3)                                                   0.9 (0.6--1.1)   0.001
  Non-Hispanic white[d](#tfn14-ehp0116-000409){ref-type="table-fn"}                                                                                                
   Lifetime diagnosis of asthma                                                  1.6 (1.1--2.3)                                                   0.9 (0.6--1.2)   0.009
   Early-onset asthma                                                            1.3 (0.7--2.2)                                                   1.2 (0.7--1.9)   0.067
   Late-onset asthma                                                             1.8 (1.1--2.9)                                                   0.7 (0.4--1.1)   0.030
   Current wheezing                                                              1.7 (1.2--2.3)                                                   0.8 (0.5--1.0)   0.005
   Medication for wheeze                                                         1.9 (1.2--2.8)                                                   0.8 (0.5--1.2)   0.004
  Hispanic white[d](#tfn14-ehp0116-000409){ref-type="table-fn"}                                                                                                    
   Lifetime diagnosis of asthma                                                  1.2 (0.8--1.8)                                                   1.2 (0.7--1.9)   0.277
   Early-onset asthma                                                            1.1 (0.6--1.9)                                                   1.1 (0.5--1.9)   0.886
   Late-onset asthma                                                             1.3 (0.7--2.2)                                                   1.4 (0.7--2.6)   0.233
   Current wheezing                                                              1.2 (0.8--1.7)                                                   1.0 (0.6--1.4)   0.622
   Medication for wheeze                                                         1.6 (0.9--2.5)                                                   1.0 (0.5--1.6)   0.162

SNP1 (rs6591255): T→A; SNP3 (rs1695): A→G.

LRT: comparing the model with the two *GSTP1* SNPs with the model without the *GSTP1* SNPs.

Models are adjusted for communities of residence, sex, age, gestational age, smoke exposure, and Hispanic ethnicity.

Models are adjusted for communities of residence, sex, age, gestational age, and smoke exposure.

*p* \< 0.05 although the confidence upper/lower limit is 1.0.

###### 

Haplotype frequencies of four *GSTP1* htSNPs in non-Hispanic and Hispanic white participants in the CHS.

  Non-Hispanic white                                    Hispanic white                                                                                                
  ----------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------
  0100                                                  0.4804                                                  0100                                                  0.3687
  1011                                                  0.3012                                                  1011                                                  0.2188
  1000                                                  0.0832                                                  0010                                                  0.2087
  0000                                                  0.0832                                                  0000                                                  0.0990
  0010                                                  0.0078                                                  1000                                                  0.0670
  1001[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0173[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   1001[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0148[b](#tfn17-ehp0116-000409){ref-type="table-fn"}
  0110[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0083[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0111[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0081[b](#tfn17-ehp0116-000409){ref-type="table-fn"}
  1010[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0055[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0011[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0046[b](#tfn17-ehp0116-000409){ref-type="table-fn"}
  0111[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0055[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   1010[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0041[b](#tfn17-ehp0116-000409){ref-type="table-fn"}
  0011[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0033[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0001[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0029[b](#tfn17-ehp0116-000409){ref-type="table-fn"}
  0001[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0021[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0110[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0026[b](#tfn17-ehp0116-000409){ref-type="table-fn"}
  1100[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0010[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0101[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0008[b](#tfn17-ehp0116-000409){ref-type="table-fn"}
  1110[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0008[b](#tfn17-ehp0116-000409){ref-type="table-fn"}                                                         
  1101[b](#tfn17-ehp0116-000409){ref-type="table-fn"}   0.0005[b](#tfn17-ehp0116-000409){ref-type="table-fn"}                                                         

1: minor allele and 0: common allele, by the order of SNP1 (rs6591255): T → A; SNP2 (rs4147581): C → G; SNP3 (rs1695): A → G; and SNP4 (rs749174): C → T.

Haplotypes were collapsed into a single composite category in the haplotype analyses.

###### 

The association \[OR (95% CI)\] of common *GSTP1* haplotypes with asthma and wheezing in CHS participants.

  Ethnicity and haplotype                                             Lifetime diagnosis of asthma   Early-onset asthma   Current wheezing   Medication for wheeze
  ------------------------------------------------------------------- ------------------------------ -------------------- ------------------ -----------------------
  All white[a](#tfn18-ehp0116-000409){ref-type="table-fn"}                                                                                   
   h0100[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.0                            1.0                  1.0                1.0
   h0000[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.1 (0.8--1.4)                 1.1 (0.7--1.6)       1.1 (0.8--1.4)     1.0 (0.7--1.4)
   h0010[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               0.9 (0.7--1.3)                 1.2 (0.8--1.8)       0.7 (0.5--0.9)     0.7 (0.5--1.0)
   h1000[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.3 (1.0--1.7)                 1.2 (0.8--1.8)       1.1 (0.9--1.4)     1.3 (0.9--1.8)
   h1011[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.2 (1.0--1.5)                 1.3 (1.0--1.7)       1.1 (0.9--1.3)     1.2 (1.0--1.4)
   Others                                                             1.0 (0.7--1.6)                 1.3 (0.8--2.2)       1.0 (0.7--1.5)     1.0 (0.6--1.6)
   *p*-Value of LRT[c](#tfn20-ehp0116-000409){ref-type="table-fn"}    0.059                          0.253                0.055              0.045
  Non-Hispanic white[d](#tfn21-ehp0116-000409){ref-type="table-fn"}                                                                          
   h0100[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.0                            1.0                  1.0                1.0
   h0000[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               0.9 (0.7--1.3)                 0.8 (0.4--1.4)       1.1 (0.8--1.5)     1.0 (0.7--1.5)
   h0010[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               0.7 (0.2--2.3)                 1.8 (0.5--5.9)       0.7 (0.3--2.0)     0.5 (0.1--2.4)
   h1000[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.4 (1.1--2.0)                 1.2 (0.8--1.9)       1.2 (0.9--1.6)     1.4 (0.9--2.0)
   h1011[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.2 (1.0--1.5)                 1.3 (0.9--1.7)       1.1 (0.9--1.4)     1.2 (0.9--1.5)
   Others                                                             0.9 (0.6--1.5)                 1.2 (0.6--2.1)       0.9 (0.6--1.4)     0.9 (0.5--1.5)
   *p*-Value of LRT[c](#tfn20-ehp0116-000409){ref-type="table-fn"}    0.058                          0.296                0.408              0.215
  Hispanic white[d](#tfn21-ehp0116-000409){ref-type="table-fn"}                                                                              
   h0100[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.0                            1.0                  1.0                1.0
   h0000[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.4 (0.9--2.2)                 1.6 (0.9--3.1)       1.0 (0.6--1.5)     0.9 (0.5--1.6)
   h0010[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.1 (0.7--1.6)                 1.3 (0.7--2.2)       0.8 (0.5--1.1)     0.8 (0.5--1.3)
   h1000[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.0 (0.5--1.8)                 1.2 (0.5--2.6)       0.9 (0.6--1.6)     1.2 (0.7--2.2)
   h1011[b](#tfn19-ehp0116-000409){ref-type="table-fn"}               1.4 (1.0--2.1)                 1.4 (0.8--2.4)       1.1 (0.8--1.6)     1.2 (0.8--1.9)
   Others                                                             1.6 (0.8--3.3)                 2.0 (0.8--5.1)       1.4 (0.7--2.8)     1.4 (0.6--3.2)
   *p*-Value of LRT[c](#tfn20-ehp0116-000409){ref-type="table-fn"}    0.257                          0.407                0.460              0.501

Models are adjusted for communities of residence, sex, age, gestational age, smoke exposure, and Hispanic ethnicity.

1: minor allele and 0: common allele, by the order of SNP1 (rs6591255): T → A; SNP2 (rs4147581): C → G; SNP3 (rs1695): A → G; and SNP4 (rs749174): C → T.

LRT (likelihood ratio test): the omnibus test of haplotype association.

Models are adjusted for communities of residence, sex, age, gestational age, and smoke exposure.

###### 

Joint effect of *in utero* exposure \[OR (95% CI)\] to maternal smoking and *GSTP1* haplotype h0010 with asthma and wheezing outcomes, non-Hispanic and Hispanic whites combined.[a](#tfn22-ehp0116-000409){ref-type="table-fn"}

                                                                               *In utero* exposure to maternal smoking   
  ---------------------------------------------------------------------- ----- ----------------------------------------- ----------------
  Lifetime diagnosis of asthma                                           No    1.0                                       1.1 (0.7--1.6)
                                                                         Yes   1.2 (0.9--1.5)                            1.4 (0.9--2.0)
  Early-onset asthma                                                     No    1.0                                       1.7 (0.9--2.9)
                                                                         Yes   1.4 (0.9--1.9)                            2.0 (1.1--3.3)
  Late-onset asthma                                                      No    1.0                                       0.7 (0.3--1.3)
                                                                         Yes   1.1 (0.8--1.5)                            1.0 (0.6--1.7)
  Current wheezing[b](#tfn23-ehp0116-000409){ref-type="table-fn"}        No    1.0                                       1.2 (0.7--1.7)
                                                                         Yes   0.9 (0.7--1.1)                            1.9 (1.3--2.6)
  Medication for wheeze[b](#tfn23-ehp0116-000409){ref-type="table-fn"}   No    1.0                                       0.9 (0.5--1.5)
                                                                         Yes   1.1 (0.8--1.3)                            1.9 (1.2--2.8)

Models are adjusted for ethnicity, communities of residence, sex, age, gestational age, and secondhand-smoke exposure.

Significant interaction between *in utero* exposure to maternal smoking and *GSTP1* haplotype h0010.

###### 

Joint effect of *in utero* exposure \[OR (95% CI)\] to maternal smoking and *GSTP1* haplotype h1011 with asthma and wheezing outcomes, non-Hispanic and Hispanic whites combined.[a](#tfn24-ehp0116-000409){ref-type="table-fn"}

                                       *In utero* exposure to maternal smoking   
  ------------------------------ ----- ----------------------------------------- ----------------
  Lifetime diagnosis of asthma   No    1.0                                       1.2 (0.8--1.7)
                                 Yes   1.3 (1.0--1.6)                            1.5 (0.9--2.1)
  Early-onset asthma             No    1.0                                       1.7 (1.0--2.8)
                                 Yes   1.4 (1.0--1.9)                            1.9 (1.0--3.1)
  Late-onset asthma              No    1.0                                       0.8 (0.4--1.4)
                                 Yes   1.3 (0.9--1.7)                            1.2 (0.6--1.9)
  Current wheezing               No    1.0                                       1.4 (0.9--2.0)
                                 Yes   1.1 (0.9--1.3)                            2.1 (1.4--3.0)
  Medication for wheeze          No    1.0                                       1.3 (0.8--2.1)
                                 Yes   1.4 (1.0--1.7)                            2.0 (1.2--3.1)

Models are adjusted for ethnicity, communities of residence, sex, age, gestational age, and secondhand-smoke exposure.

###### 

Joint effect of *in utero* exposure \[OR (95% CI)\] to maternal smoking and *GSTP1* Ile105Val genotypes with wheezing outcomes, non-Hispanic and Hispanic whites combined.[a](#tfn25-ehp0116-000409){ref-type="table-fn"}

                                                                                              *In utero* exposure to maternal smoking   
  ---------------------------------------------------------------------- -------------------- ----------------------------------------- ----------------
  Lifetime diagnosis of asthma                                           Ile/Ile              1.0                                       1.1 (0.7--1.6)
                                                                         Ile/Val or Val/Val   1.2 (0.9--1.5)                            1.4 (0.9--2.0)
  Early-onset asthma                                                     Ile/Ile              1.0                                       1.7 (0.9--2.9)
                                                                         Ile/Val or Val/Val   1.4 (0.9--1.9)                            2.0 (1.1--3.3)
  Late-onset asthma                                                      Ile/Ile              1.0                                       0.7 (0.3--1.3)
                                                                         Ile/Val or Val/Val   1.1 (0.8--1.5)                            1.0 (0.6--1.7)
  Current wheezing[b](#tfn26-ehp0116-000409){ref-type="table-fn"}        Ile/Ile              1.0                                       1.2 (0.7--1.7)
                                                                         Ile/Val or Val/Val   1.0 (0.7--1.1)                            1.9 (1.3--2.6)
  Medication for wheeze[b](#tfn26-ehp0116-000409){ref-type="table-fn"}   Ile/Ile              1.0                                       0.9 (0.5--1.5)
                                                                         Ile/Val or Val/Val   1.1 (0.8--1.3)                            1.9 (1.2--2.8)

Models are adjusted for ethnicity, communities of residence, sex, age, gestational age, and secondhand-smoke exposure.

Significant interaction between *in utero* exposure to maternal smoking and *GSTP1* genotypes (*p* = 0.035 for current wheezing and *p* = 0.043 for medication for wheeze).
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